Enterprise Value

153M

Cash

597M

Avg Qtr Burn

-16.09M

Short % of Float

2.25%

Insider Ownership

27.21%

Institutional Own.

52.87%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Taletrectinib (ROS1 inhibitor) Details
Cancer, Non-small cell lung carcinoma

Phase 2

Data readout

NUV-1511 Details
Solid tumor/s

Phase 1/2

Data readout

NUV-868 +enzalutamide Details
Cancer, Solid tumor/s, Castration-resistant prostate cancer

Phase 1b

Data readout

NUV-868 +olaparib Details
Solid tumor/s, Cancer, Pancreatic cancer, Ovarian cancer, Castration-resistant prostate cancer, Triple-negative breast cancer

Phase 1b

Data readout

Phase 1

Data readout

NUV-422 (CDK inhibitor) Details
High-grade Glioma , Solid tumor/s, Cancer, Prostate cancer, Breast cancer, Castration-resistant prostate cancer, Metastatic breast cancer

Failed

Discontinued